Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

STATUS

Recruiting
participants needed

54
sponsor

University of Pennsylvania

Send

Updated on 19 February 2024

See if I qualify

measurable disease

multiple myeloma

Summary

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

Description

Tasquinimod has previously been studied as an anti-cancer agent in patients with other cancers, including a phase 3 randomized trial in patients with metastatic prostate cancer that showed an improvement in radiographic progression-free survival. The side effect profile of tasquinimod is well-characterized based on this previous experience. This trial will establish a maximum tolerated dose and optimal schedule for administration of tasquinimod in patients with multiple myeloma and then investigate the maximum tolerated dose of tasquinimod in combination with a standard myeloma regimen of ixazomib, lenalidomide, and dexamethasone (IRd). For both single agent tasquinimod and the combination of tasquinimod with IRd, exploratory expansion cohorts will be enrolled to preliminarily characterize the antimyeloma activity of each regimen.

Details

Condition	Multiple Myeloma, Multiple Myeloma, Lymphoproliferative Disorder
Age	18years - 100years
Treatment	Tasquinimod, IRd chemotherapy
Clinical Study Identifier	NCT04405167
Sponsor	University of Pennsylvania
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Signed informed consent'
	b'18 years of age or older'
	b'Multiple myeloma (MM) diagnosed according to IMWG criteria'
	b'Measurable disease (this is defined differently in different arms)'
	b'Multiple myeloma relapsed or refractory to treatment (this is defined differently in'
	b'different arms)'
	b'Meet certain clinical laboratory criteria'
	b'ECOG performance status \\u22642'
	b'Life expectancy of at least 3 months'
	b'For women of childbearing potential, a negative serum or urine pregnancy test prior to'
	b'tudy treatment.'
	b'For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile'
	b'(absence of ovaries and/or uterus): agreement to use two methods of contraception one'
	b'of which must be highly effective'
	b'For men: agreement to use a barrier method of contraception for 1 month before start'
	b'of study treatment, during the treatment period and for 6 months after the last dose'
	b'of study treatment.'
Exclusion Criteria
	b'Failure to have fully recovered (i.e. \\u2264 Grade 1 toxicity) from the effects of prior'
	b'chemotherapy (except for alopecia)'
	b'Active graft versus host disease'
	b'Treatment with any of the following:'
	b'Cytotoxic chemotherapy within 3 weeks prior to the initiation of study treatment'
	b'Proteasome inhibitors, Imids, or monoclonal antibodies within 2 weeks prior to'
	b'the initiation of study treatment'
	b'Experimental therapy within 4 weeks or 5 half-lives, whichever is shorter'
	b'Systemic corticosteroids >=10 mg prednisone or equivalent within 7 days prior to'
	b'the initiation of study treatment'
	b'Radiotherapy within 7 days prior to initiating study treatment'
	b'Plasmapheresis within 4 weeks prior to the initiation of study treatment'
	b'Tasquinimod at any time'
	b'Known central nervous system involvement by myeloma'
	b'Diagnosis of smoldering multiple myeloma'
	b'Diagnosis of POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,'
	b'endocrinopathy, monoclonal protein, and skin changes)'
	b'Active plasma cell leukemia'
	b'Symptomatic primary (AL) amyloidosis'
	b'Diagnosis of myelodysplastic syndrome or myeloproliferative syndrome'
	b'Active other malignancy'
	b'Major surgery within 4 weeks prior to initiating study treatment'
	b'Evidence of severe or currently uncontrolled cardiovascular condition'
	b'Ongoing or active systemic infection that requires systemic antibiotic or parenteral'
	b'anti-infective therapy'
	b'Active tuberculosis, active hepatitis A, B or C virus infection, or known human'
	b'immunodeficiency virus (HIV) positive'
	b'History of pancreatitis'
	b'History of malabsorption or other condition that would interfere with absorption of'
	b'tudy drugs'
	b'Systemic treatment within 14 days prior to the initiation of study treatment with'
	b'moderate or strong inhibitor or moderate or strong inducer of cytochrome P-3A4'
	b'(CYP3A4)'
	b'Need for ongoing therapy drug substances of narrow therapeutic range that are'
	b'metabolized mainly by CYP3A4 (alfentanil, fentanyl, quinidine, astemizole,'
	b'terfenadine, sirolimus, tacrolimus, cyclosporine, cisapride, ergotamine)'
	b'Need for ongoing therapy with drug substances of narrow therapeutic range metabolized'
	b'mainly by CYP1A2 (duloxetine, alosetron, theophylline, tizanidine, ondansetron)'
	b'Ongoing treatment with warfarin, unless the INR is <=3.0.'
	b'For subjects enrolled on the IRd combination arms, prior dose-limiting toxicity with'
	b'lenalidomide or ixazomib or absolute contraindication to concomitant thrombosis'
	b'prophylaxis'
	b'Peripheral neuropathy grade \\u22652 (NCI-CTCAE)'
	b'Known hypersensitivity to tasquinimod or any excipients in the study treatments'
	b'Pregnant or nursing (lactating) women'
	b"Any other condition that would, in the Investigator's judgment, contraindicate"
	b"ubject's participation in the clinical study due to safety concerns or compliance"
	b'with clinical study procedures'
	b'Prior inclusion in this study'

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

Harjeet K Sembhi, MPH

Primary Contact

University of Pennsylvania

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

measurable disease

multiple myeloma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Summary

Description

Details

How to participate?

Harjeet K Sembhi, MPH

University of Pennsylvania

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Summary

Description

Details

How to participate?

Harjeet K Sembhi, MPH

University of Pennsylvania

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Sign up as a volunteer to stay informed

Study AnnotationsStudy Notes

Add a private note

Send Notes

Study Definition

Add a private note